Showing results (221-230 of 345) with videos related to
Sort By:
Pageof 35
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2007
Mesothelin expression in human lung cancerMitchell Ho, Tapan K Bera, Mark C Willingham, et al.Proceedings of the National Academy of Sciences of the United States of America|November 1, 1990
The recombinant immunotoxin anti-Tac(Fv)-Pseudomonas exotoxin 40 is cytotoxic toward peripheral blood malignant cells from patients with adult T-cell leukemiaR J Kreitman, V K Chaudhary, T Waldmann, et al.The Journal of Cell Biology|February 1, 1994
Expression of a dominant allele of human ARF1 inhibits membrane traffic in vivoC J Zhang, A G Rosenwald, M C Willingham, et al.Carcinogenesis|July 19, 2003
Alterations in genomic profiles during tumor progression in a mouse model of follicular thyroid carcinomaHao Ying, Hideyo Suzuki, Hiroko Furumoto, et al.Cancer Research|February 20, 2007
NGEP, a prostate-specific plasma membrane protein that promotes the association of LNCaP cellsSudipto Das, Yoonsoo Hahn, Satoshi Nagata, et al.Oncogene|November 30, 2005
PPARgamma insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-kappaB signaling pathwayY Kato, H Ying, L Zhao, et al.Cancer Research|February 1, 1985
Anti-transferrin receptor antibody linked to Pseudomonas exotoxin as a model immunotoxin in human ovarian carcinoma cell linesR Pirker, D J FitzGerald, T C Hamilton, et al.Journal of Cancer Research and Clinical Oncology|March 6, 2003
19-nor-1alpha,25-dihydroxyvitamin D(2) (paricalcitol): effects on clonal proliferation, differentiation, and apoptosis in human leukemic cell linesIstván Molnár, Timothy Kute, Mark C Willingham, et al.Journal of Cellular Physiology|September 1, 1984
Verapamil enhances the toxicity of conjugates of epidermal growth factor with Pseudomonas exotoxin and antitransferrin receptor with Pseudomonas exotoxinS Akiyama, M M Gottesman, J A Hanover, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2007
Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancersRaffit Hassan, Susie Bullock, Ahalya Premkumar, et al.Pageof 35